Oyster Point Pharma

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Oyster Point Pharma sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Oyster Point Pharma: 10 sponsored US clinical trials, none currently recruiting.

Oyster Point Pharma sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 3 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Long Term Follow up Dry Eye Disease, with 1 trials.

Top-decile sponsor footprint

Oyster Point Pharma ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

TERMINATED Phase 4

A Study Evaluating the Safety of the Nasal Pump

NCT06329687
COMPLETED Phase 4

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

NCT05918406
COMPLETED Phase 2

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

NCT04957758
COMPLETED Phase 1

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

NCT04072146
COMPLETED Phase 3

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT04036292
COMPLETED Phase 2

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
COMPLETED Phase 2

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
COMPLETED Phase 2

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03636061
COMPLETED Phase 2

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

NCT03633461
COMPLETED Phase 2

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

NCT03452397

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 1
Phase 4 2

Therapeutic Areas

Long Term Follow up Dry Eye Disease 1
Dry Eye Disease (DED) 1
Dry Eye Disease 1

How the Oyster Point Pharma early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 9 completed (90%).

Phase mix: 3 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Long Term Follow up Dry Eye Disease (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Oyster Point Pharma: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Oyster Point Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Oyster Point PharmaAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Oyster Point Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Oyster Point Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Oyster Point Pharma page

10 registered trials is a research-attention snapshot, not an endorsement of Oyster Point Pharma or any single study.

  • None of Oyster Point Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Long Term Follow up Dry Eye Disease is the condition Oyster Point Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Long Term Follow up Dry Eye Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Oyster Point Pharma pipeline card: 10 registered trials from official public datasets.Report a data error.